| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 01/21/2010 | WO2010007382A1 Benzazepine derivatives and their use as hstamine h3 antagonists |
| 01/21/2010 | WO2010007381A1 Antibacterial combination therapy for the treatment of gram positive bacterial infections |
| 01/21/2010 | WO2010007374A1 Pharmaceutical compounds |
| 01/21/2010 | WO2010007332A2 Composition of soluble indigestible fibre and of eukaryotic organisms with a polysaccharide wall, used in the well-being field |
| 01/21/2010 | WO2010007331A2 Composition of soluble indigestible fibre and of microalgae used in the well-being field |
| 01/21/2010 | WO2010007318A2 Novel imidazo[1,2-a]pyrimidine derivatives, method for the preparation thereof, use thereof as medicaments, pharmaceutical compositions and novel use in particular as met inhibitors |
| 01/21/2010 | WO2010007317A1 Novel imidazo[1,2-a]pyridine derivatives, method for the preparation thereof, use thereof as medicaments, pharmaceutical compositions and novel use in particular as met inhibitors |
| 01/21/2010 | WO2010007316A2 Novel triazolo(4,3-a)pyridine derivatives, process for the preparation thereof, use thereof as medicaments, pharmaceutical compositions and novel use, in particular as met inhibitors |
| 01/21/2010 | WO2010007252A2 Formulation for improving the bioavailability of a hydrophobic molecule |
| 01/21/2010 | WO2010007248A2 Novel tricyclic derivatives, process for the preparation thereof and pharmaceutical compositions containing same |
| 01/21/2010 | WO2010007232A1 Novel rapid-effect pharmaceutical forms and uses of resulting pharmaceutical compositions |
| 01/21/2010 | WO2010007181A2 New salt forms of an aminoindan derivative |
| 01/21/2010 | WO2010007179A1 Heterocyclic derivatives that are used in the treatment of neurodegenerative diseases |
| 01/21/2010 | WO2010007176A1 Inhbitors of mrp4 and agents stimulating mrp4 activity for the treatment of cardiac disorders |
| 01/21/2010 | WO2010007175A2 Pacap signaling pathway modulators for treating inflammatory skin diseases with a neurogenic component, and more particularly rosacea and composition containing them |
| 01/21/2010 | WO2010007169A1 Pharmaceutical compositions comprising lignans and their derivatives for treating hyperplastic diseases |
| 01/21/2010 | WO2010007120A1 Pyridazine derivatives as smo inhibitors |
| 01/21/2010 | WO2010007116A2 New chemical compounds |
| 01/21/2010 | WO2010007114A2 New chemical compounds |
| 01/21/2010 | WO2010007100A1 7-substituted amino triazoles as pi3k inhibitors |
| 01/21/2010 | WO2010007099A1 2-aminoimidazo[1,2-b]pyridazine derivatives as pi3k inhibitors |
| 01/21/2010 | WO2010007085A2 Use of organic compounds |
| 01/21/2010 | WO2010007074A1 Pyrazolo [1, 5-a] pyrimidine derivatives |
| 01/21/2010 | WO2010007073A1 Piperazine derivatives used as cav2.2 calcium channel modulators |
| 01/21/2010 | WO2010007072A1 Piperazine derivatives used as cav2.2 calcium channel modulators |
| 01/21/2010 | WO2010007034A1 Use of pyrimidylaminobenzamide derivatives for the treatment of fibrosis |
| 01/21/2010 | WO2010007032A1 Piperidine based ureas as nk1 antagonists |
| 01/21/2010 | WO2010007027A1 Selective hydroxamic acid based mmp-12 and mmp-13 inhibitors |
| 01/21/2010 | WO2010007016A1 Method for manufacturing medicinal compounds containing dabigatran |
| 01/21/2010 | WO2010006982A1 Mimetics of sulfated oligosaccharides |
| 01/21/2010 | WO2010006973A2 Compositions and methods for inhibiting expression of tgf-beta receptor genes |
| 01/21/2010 | WO2010006970A1 Novel phenylimidazopyrazines |
| 01/21/2010 | WO2010006962A1 Derivatives of triazines and uracils, their preparation and their application in human therapeutics |
| 01/21/2010 | WO2010006947A1 Novel phenyl-imidazopyridines and pyridazines |
| 01/21/2010 | WO2010006945A1 Substituted indolyl and indazolyl derivatives and uses thereof |
| 01/21/2010 | WO2010006944A1 Aminotetrahydroindazoloacetic acids |
| 01/21/2010 | WO2010006940A1 Tetrahydrocinnolines as 11 beta hsd1 inhibitors for diabetes |
| 01/21/2010 | WO2010006939A1 Aminotetrahydroindazoloacetic acids |
| 01/21/2010 | WO2010006938A1 Novel heterocyclyl compounds for treatment of cardiovascular disease |
| 01/21/2010 | WO2010006929A1 Pharmaceutical compositions comprising levetiracetam |
| 01/21/2010 | WO2010006904A2 New crystalline forms of rabeprazole sodium |
| 01/21/2010 | WO2010006817A1 Supplementation of propane-1,2,3-triol and water in fasting subjects |
| 01/21/2010 | WO2010006792A1 Synthesis of cyclic amidines |
| 01/21/2010 | WO2010006704A1 Oxazolopyrimidines as edg-1 receptor agonists |
| 01/21/2010 | WO2010006697A2 Powders for reconstitution |
| 01/21/2010 | WO2010006521A1 2-methyl-5h-pyrazolo[1,5-a][3,1]benzoxazin-5-imine compound, the preparation and the use thereof |
| 01/21/2010 | WO2010006498A1 Method for preparing reduced type coenzyme q10 |
| 01/21/2010 | WO2010006496A1 Compounds of estrogen-related receptor modulators and the uses thereof |
| 01/21/2010 | WO2010006485A1 Benzoxazinopyrazoles and their ring-opening compound |
| 01/21/2010 | WO2010006451A1 Dosage form containing a statin |
| 01/21/2010 | WO2010006438A1 Thiosemicarbazone inhibitor compounds and cancer treatment methods |
| 01/21/2010 | WO2010006432A1 Pharmaceutical compositions comprising ret inhibitors and methods for the treatment of cancer |
| 01/21/2010 | WO2010006392A2 Pharmaceutical formulation between jasmonates and it derivatives and nanocarries or microcarri es |
| 01/21/2010 | WO2010006376A1 Compositions comprising tea tree oil and methods for the prevention and treatment of cancer |
| 01/21/2010 | WO2009146033A3 Compositions and methods for modulating smn activity |
| 01/21/2010 | WO2009145424A3 Anti-peptic ulcer composition comprising rice prolamin |
| 01/21/2010 | WO2009144514A3 Cooperative induction of apoptosis of prostate tissue - prostate cancer prevention - new practice of peripheral androgenic exclusion construction of complex tablet |
| 01/21/2010 | WO2009143403A8 Combination therapy for the management hypertension |
| 01/21/2010 | WO2009143359A3 Amido anti-viral compounds |
| 01/21/2010 | WO2009141718A3 Process for the preparation of prostaglandin analogues and intermediates thereof |
| 01/21/2010 | WO2009139004A3 Tat dna sequences, gene constructs, vaccine and processes thereof |
| 01/21/2010 | WO2009137291A3 Spiroazaindoles |
| 01/21/2010 | WO2009137133A3 5-substituted-2-imino-thiazolidinone compounds and their use as inhibitors of bacterial infection |
| 01/21/2010 | WO2009137130A3 Antibacterial fluoroquinolone analogs |
| 01/21/2010 | WO2009136408A4 Synergistic pharmaceutical cocrystals |
| 01/21/2010 | WO2009135651A8 6-pyridin-3-yl-3,4-dihydro-1h-quinolin-2-one derivatives and related compounds as inhibitors of the human aldosterone synthase cyp11b2 |
| 01/21/2010 | WO2009134967A3 Use of nucleic acids with reduced pressure therapy for treating wounds |
| 01/21/2010 | WO2009134723A9 Progesterone antagonists such as cdb-4124 in the treatment of breast cancer |
| 01/21/2010 | WO2009134383A3 Vinyl substituted fatty acids |
| 01/21/2010 | WO2009134086A3 Pharmaceutical formulation for treatment of cardiovascular disease |
| 01/21/2010 | WO2009134079A3 Pharmaceutical formulation |
| 01/21/2010 | WO2009134053A3 Pharmaceutical composition containing thiazide-based compound with controlled release and angiotensin-ii-receptor blocker |
| 01/21/2010 | WO2009131493A3 5-hydroxy-4-aminomethyl-1-cyclohexane or (cycloheptyl)--3-alkoxycarbonyl indole derivatives, pharmaceutically acceptable antiviral salts thereof and a method for the production thereof |
| 01/21/2010 | WO2009130735A4 Fatty acid derivatives for oral administration endowed with high paia- tability |
| 01/21/2010 | WO2009129510A3 Sulindac formulations in a biodegradable material |
| 01/21/2010 | WO2009129433A3 Alpha adrenergic receptor agonists for treatment of degenerative disc disease |
| 01/21/2010 | WO2009124184A3 Azabenzanthrones for the treatment of viral infections, cancer or restenosis |
| 01/21/2010 | WO2009124044A3 Tumor growth inhibition via conditioning of tumor microenvironment |
| 01/21/2010 | WO2009121600A3 Hydroxytyrosol formulations for the treatment and prevention of dna oxidative damages in post-menopausal conditions |
| 01/21/2010 | WO2009120885A3 Stabilizing lipid compositions for oral pharmaceutical agents |
| 01/21/2010 | WO2009120799A9 Methods of treating fibrotic disorders |
| 01/21/2010 | WO2009120192A3 Processes for the preparation of benzo-fused dioxin derivatives |
| 01/21/2010 | WO2009117710A3 Methods of treating inflammation |
| 01/21/2010 | WO2009115927A3 Nucleotide analogues with quaternary carbon stereogenic centers and methods of use |
| 01/21/2010 | WO2009115652A3 Bitherapy and tritherapy used for treating an hiv-positive patient |
| 01/21/2010 | WO2009113091A3 Pharmaceutical compositions comprising valsartan |
| 01/21/2010 | WO2009112677A3 Bicyclic derivatives of azabicyclic carboxamides, preparation thereof and therapeutic use thereof |
| 01/21/2010 | WO2009104916A9 Pharmaceutical formulations for the treatment of cardiovascular diseases |
| 01/21/2010 | WO2009104911A4 Uses as agents for prophylaxis or treatment of cervical cancer |
| 01/21/2010 | WO2009102845A3 Food products containing omega-3 fatty acids |
| 01/21/2010 | WO2009099634A3 Picoplatin and amrubicin to treat lung cancer |
| 01/21/2010 | WO2009091764A3 Beta-lactams for the treatment of glaucoma, ocular hypertension, baldness and hair loss |
| 01/21/2010 | WO2009059961A3 A method of hormone suppression in humans |
| 01/21/2010 | WO2009046841A8 Piperidine and piperazine derivatives for treating tumours |
| 01/21/2010 | WO2009026315A3 Use of carbon nanotube for drug delivery |
| 01/21/2010 | WO2009018492A3 Micro-rnas that control myosin expression and myofiber identity |
| 01/21/2010 | WO2008156092A8 Azolylmethylidenehydrazine derivative and use thereof |
| 01/21/2010 | WO2008146251A9 A primary micro rna expression cassette |
| 01/21/2010 | WO2008144730A3 Stable pharmaceutical formulation for a dpp-iv inhibitor |
| 01/21/2010 | WO2008144269A3 Methods for using vasopressin antagonists with anthracycline chemotherapy agents to reduce cardiotoxicity and/or improve survival |